Salute e Benessere

Director/PDMR Shareholding

DXS INTERNATIONAL PLC(AQSE: DXSP)Notification of Director / PDMR DealingDXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 6 November 2024 Mr Bob Sutcliffe, the Chairman, purchased a total of 35,000 Ordinary Shares in the Company at a price of 1.3p per share. Following this transaction Mr...

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio…

BOSTON and LONDON, Nov.08, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the...

Notification of managers' transactions

ANNOUNCEMENT NO. 284 8 November 2024 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of the Vice Chair of ChemoMetec's Board of Directors Martin Glensbjerg in the attached PDF document.For further...

Notification of managers' transactions

ANNOUNCEMENT NO. 283 8 November 2024 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of the CEO Martin Helbo Behrens in the attached PDF document.For further information, please contact:Kim...

Step up, show up: Dubai's annual walkathon WeWalk returns in fight against…

His Excellency Ahmed Al Suwaidi, CEO of Dubai Charity Association, said: "We at Dubai Charity Association are pleased to cooperate with TECOM Group PJSC in organising the fifth edition of our annual charity event WeWalk, which mirrors the key pillars of our strategy and corporate values. Dubai Charity Association has always been keen on promoting charitable work and fostering social cohesion and human interaction amongst various segments of society, in line with our visionary leadership's…

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 -…

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis (3)and at constant exchange rates (CER)EBITDA (1)of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income (2)of € 445.4 million, +9.5%Net income of € 338.4 million, +11.1%Free cash flow (4)at € 434.3 million, +€ 42.5 million vs prior yearNet debt (5)at € 1,317.3 million, just below 1.6x EBITDA...

Implantica presents the third quarter 2024 on November 15 at 15:00 CEST

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica...

Coway Announces Financial Results for Q3 FY2024

Coway's reported earnings are as follows: Coway's reported earnings are as follows: * The reported figures are taken from the consolidated K-IFRS (International Financial Reporting Standards) statement. Cumulative revenue for 2024 now stands atKRW 3,184.4billion (+7.5% YoY) with an operating profit of KRW 612.0 billion (+8.3% YoY). InSouth Korea, domestic business generatedKRW 660.8 billionin revenue for the third quarter, up 9.9% from last year. This increase has been...

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC…

Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said: "Using our integrated 'right targets, right vectors, right patients, right time' approach, we aim to address the unmet clinical need for durably effective, accessible therapies, to save lives by preventing or significantly delaying disease recurrence for cancer patients. We combine our deep knowledge of the field of immunology with our uniquely sensitive AI/ML Precision ImmunomicsTM platform to identify and select…

'ESSE' Maker KT&G Expands Presence in Europe with Romania Entry, Achieving…

In the third quarter, the growth of the main business centered on the tobacco sector continued. In particular, the growth of the overseas cigarette business stood out. In the third quarter, revenue of the overseas cigarette business reached KRW 419.7 billion, up 30.5% year-over-year, setting a new record in revenue for two consecutive quarters, while sales volume and operating profit also increased by 10.1% and 167.2%, respectively, achieving "growth trifecta" in sales volume, revenue…

Fapon Highlights Innovative IVD Total Solutions and Localization Services at…

At the exhibition, Fapon will present a suite of total solutions across various technology applications, including CLIA, biochemistry, NGS, PCR, LFA and FIA for both clinical diagnostic labs and POCT scenarios. Leveraging its strong foundation in IVD technologies, Fapon integrates raw materials, reagent services, and open-system instruments into IVD total solutions. This approach ensures reliable, versatile, and seamless services for our IVD partners, particularly local IVD companies and…

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025)…

BioArctic's report for the third quarter 2024 will be published on November 14 at 08.00 a.m. CET. BioArctic's report for the third quarter 2024 will be published onNovember 14at08.00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, onNovember 8, 2024, at05.00 a.m. CET. For...

Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 |…

Key Takeaways from the Respiratory Disease Testing Market Report Key Takeaways from the Respiratory Disease Testing Market Report To read more about the latest highlights related to the respiratory disease testing market, get a snapshot of the key highlights entailed in the Global Respiratory Disease Testing Market Report Respiratory Disease Testing Overview Respiratory disease testing is a critical aspect of diagnosing and managing various conditions that affect the lungs and...

GENFIT Reports Third Quarter 2024 Financial Information

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024-GENFIT (Nasdaq and Euronext: GNFT), a...

Global Medical Tapes Market Growth Driven by Aging Population and Healthcare…

The report on the medical tapes segments the market by product type—fabric, paper, plastic—and by application, focusing on wound care, surgery, and other uses. End users are categorized into hospitals and clinics and ambulatory surgical centers. The market is driven by increased healthcare expenditure, technological advances, and the rising prevalence of chronic diseases. It also addresses challenges such as high costs and regulatory complexities while identifying opportunities such as the…

A New Era in Medicine: How Antibody Drugs are Revolutionizing Healthcare

This study provides a comprehensive look at the different types of antibody drugs, including human, humanized, chimeric, and murine for the treatment of various diseases. This study provides a comprehensive look at the different types of antibody drugs, including human, humanized, chimeric, and murine for the treatment of various diseases. The report includes market projections, regulatory information, and updates on new products and technologies. It also profiles the leading makers of...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 7 November 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...

Ipsen - October 2024 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 October 202483,814,526Gross...

Safe out of receivership

Safe out of receivershipFleurieux-sur-l'Arbresle-France - November 6, 2024, 6.00 p.m.Safe SA and its subsidiaries announce that they have emerged from the court-ordered receivership proceedings by virtue of a ruling handed down by the Pontoise Commercial Court on Wednesday November 6, 2024, in accordance with the ruling of November 5, 2024. The latter validated the recovery plans as well as the new strategy instilled and implemented by the new management team since...

Ramsay Sante : Q1 results as of September 30, 2024

PRESS RELEASE PRESS RELEASE Paris, 7 thNovember 2024 Q1 results as of September 30, 2024Unaudited group revenue increased by 8.6% to €1.18bn supported by price increases and volume growth in France and Sweden reflecting sustained patient need for healthcare and the capacity of the group's facilities to provide more care services despite staffing challenges from competition for nurses in Europe. Revenue growth on a like-for-like basis was 5.9%...

Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its…

BOSTON, Nov. 7, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced the company will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference, highlighting preclinical data supporting two clinical-stage assets, DF6215, its engineered IL-2 cytokine, and DF9001, its EGFR-targeting TriNKET, for the treatment of advanced solid tumors. BOSTON , Nov. 7, 2024 ...

Growth in revenue and operating profit

Trading statement for Q1 2024/25 (1 July - 30 September 2024) Growth in revenue and operating profitRevenue was up 27% in the first quarter of 2024/25 to DKK 115.6 million from DKK 91.1 million in the year-earlier period. The performance reflects growing sales of both instruments, consumables and services. Operating profit (EBITDA) was up 50% in the first quarter to DKK 62.1 million, driven by the revenue growth. The EBITDA margin was 54% for the first quarter. 2024/25 Q1 ...

Minimal Residual Disease Testing Market Worth $4.45 billion by 2031--Exclusive…

The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the extensive application of MRD testing in cases of hematological malignancies, the high recurrence rates of some cancers, and increasing investments & funding for MRD testing & research. However, stringent regulatory frameworks and the high costs of MRD testing restrain the growth of this market. The growth of the minimal residual disease testing market is driven by the growing…

Global Human Hair Wigs and Extensions Market Poised to Reach USD 9.3 Billion by…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Human Hair Wigs and Extensions Market Overview Geographic Dominance : Geographically,North Americadominates the Human Hair Wigs and Extensions market, withthe United Statesbeing the largest consumer. The region's...

Altri Comunicati